Manoj Soman, Asmita Indurkar, Thomas George, Jay U Sheth, Unnikrishnan Nair
{"title":"Rapid Onset Neovascular Glaucoma due to COVID-19-related Retinopathy.","authors":"Manoj Soman, Asmita Indurkar, Thomas George, Jay U Sheth, Unnikrishnan Nair","doi":"10.5005/jp-journals-10078-1356","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To present a case of rapid onset on neovascular glaucoma following the Coronavirus disease 2019 (COVID-19).</p><p><strong>Background: </strong>COVID-19 has various ocular manifestations such as conjunctivitis, uveitis, retinal vasculitis, and so on. However, to date, the development of neovascular glaucoma has not been reported in COVID-19.</p><p><strong>Case description: </strong>A 50-year-old male with a history of COVID-19 3 weeks ago presented with left eye (OS) central retinal artery occlusion (CRAO) and right eye (OD) cystoid macular edema with disc and microvascular leakage on multimodal imaging. After being managed conservatively for 2 weeks, the patient developed OD neovascular glaucoma with intraocular pressure (IOP) of 44 mm Hg and angle neovascularization (NVA) on gonioscopy. The patient was started on topical antiglaucoma medications (AGM) with panretinal photocoagulation (PRP) and responded well with complete regression of NVA, CME, and normal IOP after 3 weeks.</p><p><strong>Conclusion: </strong>This is the first reported case of rapid onset of NVG secondary to COVID-19-induced retinal vasculitis. COVID-19-associated prothrombotic state with secondary retinal vascular involvement can potentially trigger such NVG. Such NVG responds well with topical AGM and PRP therapy.</p><p><strong>Clinical significance: </strong>Given the global COVID-19 pandemic, it is imperative to be vigilant regarding the various vision-threatening manifestations associated with the disease such as the NVG.</p><p><strong>How to cite this article: </strong>Soman M, Indurkar A, George T, <i>et al.</i> Rapid onset Neovascular Glaucoma due to COVID-19-related Retinopathy. J Curr Glaucoma Pract 2022;16(2):136-140.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"136-140"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/54/jocgp-16-136.PMC9452705.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Glaucoma Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10078-1356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Aim: To present a case of rapid onset on neovascular glaucoma following the Coronavirus disease 2019 (COVID-19).
Background: COVID-19 has various ocular manifestations such as conjunctivitis, uveitis, retinal vasculitis, and so on. However, to date, the development of neovascular glaucoma has not been reported in COVID-19.
Case description: A 50-year-old male with a history of COVID-19 3 weeks ago presented with left eye (OS) central retinal artery occlusion (CRAO) and right eye (OD) cystoid macular edema with disc and microvascular leakage on multimodal imaging. After being managed conservatively for 2 weeks, the patient developed OD neovascular glaucoma with intraocular pressure (IOP) of 44 mm Hg and angle neovascularization (NVA) on gonioscopy. The patient was started on topical antiglaucoma medications (AGM) with panretinal photocoagulation (PRP) and responded well with complete regression of NVA, CME, and normal IOP after 3 weeks.
Conclusion: This is the first reported case of rapid onset of NVG secondary to COVID-19-induced retinal vasculitis. COVID-19-associated prothrombotic state with secondary retinal vascular involvement can potentially trigger such NVG. Such NVG responds well with topical AGM and PRP therapy.
Clinical significance: Given the global COVID-19 pandemic, it is imperative to be vigilant regarding the various vision-threatening manifestations associated with the disease such as the NVG.
How to cite this article: Soman M, Indurkar A, George T, et al. Rapid onset Neovascular Glaucoma due to COVID-19-related Retinopathy. J Curr Glaucoma Pract 2022;16(2):136-140.
目的:报道1例新型冠状病毒病(COVID-19)后快速发病的新生血管性青光眼。背景:COVID-19有多种眼部表现,如结膜炎、葡萄膜炎、视网膜血管炎等。然而,迄今为止,在COVID-19中尚未出现新血管性青光眼的报道。病例描述:一名50岁男性,3周前有COVID-19病史,在多模态成像上表现为左眼(OS)视网膜中央动脉闭塞(CRAO)和右眼(OD)囊样黄斑水肿伴椎间盘和微血管渗漏。经保守治疗2周后,患者发展为OD型新生血管性青光眼,眼压(IOP) 44 mm Hg,角状新生血管(NVA)。患者开始使用局部抗青光眼药物(AGM)和全视网膜光凝(PRP), 3周后NVA、CME和IOP完全恢复正常,反应良好。结论:这是首例报道的新冠肺炎致视网膜血管炎继发快速NVG病例。伴有继发性视网膜血管受累的covid -19相关血栓前状态可能引发此类NVG。这种NVG对局部AGM和PRP治疗反应良好。临床意义:在新冠肺炎全球大流行的背景下,必须警惕NVG等与疾病相关的各种视力威胁表现。本文引用方式:Soman M, Indurkar A, George T,等。新型冠状病毒相关视网膜病变致快发性新生血管性青光眼中华青光眼杂志(英文版);2009;16(2):368 - 368。